A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness

Simply Wall St.03-19

AdvertisementWhy Arcutis Biotherapeutics Stock Is On Investors’ Radar Arcutis Biotherapeutics (ARQT) shares have drawn attention after a mixed stretch, with negative returns over the past week, month,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620021441?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-19 14:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620021441","market":"sg","top_or_hot":-1,"title":"A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhy Arcutis Biotherapeutics Stock Is On Investors’ Radar Arcutis Biotherapeutics (ARQT) shares have drawn attention after a mixed stretch, with negative returns over the past week, month,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/a-look-at-arcutis-biotherapeutics-arqt-valuation-after-recen\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-19 14:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/a-look-at-arcutis-biotherapeutics-arqt-valuation-after-recen><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhy Arcutis Biotherapeutics Stock Is On Investors’ Radar Arcutis Biotherapeutics (ARQT) shares have drawn attention after a mixed stretch, with negative returns over the past week, month,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/a-look-at-arcutis-biotherapeutics-arqt-valuation-after-recen\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/a-look-at-arcutis-biotherapeutics-arqt-valuation-after-recen","article_id":"2620021441","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-arqt/arcutis-biotherapeutics/news/a-look-at-arcutis-biotherapeutics-arqt-valuation-after-recen","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2620021441","pubTimestamp":1773900526,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Why Arcutis Biotherapeutics Stock Is On Investors’ Radar\nArcutis Biotherapeutics (ARQT) shares have drawn attention after a mixed stretch, with negative returns over the past week, month, and past 3 months, alongside a positive 1 year total return and a value score of 6.\nSee our latest analysis for Arcutis Biotherapeutics.\nThe recent 7 day share price return of a 7.14% decline and 30 day share price return of a 14% decline contrast with a 1 year total shareholder return of 33.98%. This...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ARQT":"Arcutis Biotherapeutics Inc."},"translate_title":"近期股价疲软后Arcutis Biotherapeutics(ARQT)估值一览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARQT":1.5},"content_text":"AdvertisementWhy Arcutis Biotherapeutics Stock Is On Investors’ Radar Arcutis Biotherapeutics (ARQT) shares have drawn attention after a mixed stretch, with negative returns over the past week, month, and past 3 months, alongside a positive 1 year total return and a value score of 6. See our latest analysis for Arcutis Biotherapeutics. The recent 7 day share price return of a 7.14% decline and 30 day share price return of a 14% decline contrast with a 1 year total shareholder return of 33.98%. This suggests shorter term momentum has cooled while longer term holders still sit on gains. If this kind of move has you thinking about where else growth stories could emerge in healthcare, it may be worth scanning 35 healthcare AI stocks With Arcutis shares pulling back in the short term despite a 1 year total return above 30% and an intrinsic discount of around 75%, the key question is whether this reflects a genuine opportunity or a market that is already pricing in future growth. Most Popular Narrative: 44.4% Undervalued Based on the most followed narrative, Arcutis Biotherapeutics’ fair value of $39.99 sits well above the last close of $22.24, which is why some investors are paying close attention to what is driving that gap.  It is almost impossible to obtain a drug label from the FDA for pediatric use, this topical non steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.  Read the complete narrative. Curious how one set of growth, margin and profitability assumptions supports a fair value almost twice the current price? The narrative connects cash generation, earnings quality and a premium future earnings multiple into a single, tight valuation story. Result: Fair Value of $39.99 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this story could be knocked off course if ZORYVE adoption slows among dermatologists or if cash flow timing slips compared with the current 2026 expectations. Find out about the key risks to this Arcutis Biotherapeutics narrative. Next Steps With sentiment split between opportunity and caution, it makes sense to move quickly and check the balance for yourself by reviewing the 5 key rewards and 1 important warning sign. Looking for more investment ideas? If you stop here, you could miss opportunities that better fit your goals, so take a few minutes to scan high quality ideas with clear, data backed filters.  Target dependable income by checking stocks that currently screen as potential 15 dividend fortresses for long term payout seekers. Hunt for quality at a discount with companies highlighted in the screener containing 26 high quality undiscovered gems, where fundamentals and lower visibility sometimes intersect. Dial down risk by focusing on companies that pass the 73 resilient stocks with low risk scores and may offer a steadier ride through market swings.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620021441","isCrawlerRequest":true}